SELE and acute myeloid leukemia: E-selectin contributes to chemotherapy resistance in AML has been targeted therapeutically in patients using the glyco-mimetic drug, GMI-1271, which improves responses to chemotherapy (Garcia-Manero et al., 2017) and is currently in a Phase III trial for relapsed and refractory AML (NCT03616470).